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Abstract
Background: The functional and clinical significance of 14-3-3 proteins in human cancers remain
largely undetermined. Earlier, we have reported differential expression of 14-3-3ζ mRNA in oral
squamous cell carcinoma (OSCC) by differential display.
Methods: The clinical relevance of 14-3-3ζ protein in oral tumorigenesis was determined by
immunohistochemistry in paraffin embedded sections of oral pre-malignant lesions (OPLs), OSCCs
and histologically normal oral tissues and corroborated by Western Blotting. Co-
immunoprecipitation assays were carried out to determine its association with NFκB, β-catenin
and Bcl-2.
Results: Intense immunostaining of 14-3-3ζ protein was observed in 61/89 (69%) OPLs and 95/
120 (79%) OSCCs. Immunohistochemistry showed significant increase in expression of 14-3-3ζ
protein from normal mucosa to OPLs to OSCCs (ptrend < 0.001). Significant increase in expression
of 14-3-3ζ protein was observed as early as in hyperplasia (p = 0.009), with further elevation in
moderate and severe dysplasia, that was sustained in OSCCs. These findings were validated by
Western blotting. Using Co-immunoprecipitation, we demonstrated that 14-3-3ζ protein binds to
NFκB, β-catenin and Bcl-2, suggesting its involvement in cellular signaling, leading to proliferation
of oral cancer cells.
Conclusion:  Our findings suggest that over-expression of 14-3-3ζ is an early event in oral
tumorigenesis and may have an important role in its development and progression. Thus, 14-3-3ζ
may serve as an important molecular target for designing novel therapy for oral cancer.
Background
Squamous cell carcinoma of Head and Neck, including
oral cavity, is a major problem worldwide. Oral squamous
cell carcinoma (OSCC) is often preceded by development
of oral pre-malignant lesions (OPLs), of which on an aver-
age about one percent transform into cancer annually [1].
Molecular markers that can identify OPLs at high risk of
malignant transformation and predict the course of dis-
ease remain to be unequivocally proven. Currently, the
most important conventional prognostic factors for sur-
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vival of OSCC patients are histological tumor grade and
tumor stage at the time of diagnosis, including depth of
tumor invasion and involvement of regional lymph
nodes. In addition to these clinicopathological parame-
ters, molecular markers are being intensively sought and
validated for oral cancer. These new markers are being
examined for their diagnostic and prognostic impact, and
even therapeutic implications as novel drug targets. In
search of such novel targets, we recently reported
increased expression of 14-3-3ζ in oral cancer using Dif-
ferential Display [2].
14-3-3 proteins are highly conserved eukaryotic proteins
that are involved in most of the cellular processes, includ-
ing regulation of several metabolic pathways, redox regu-
lation, transcription RNA processing, protein synthesis,
folding and degradation, cell cycle, apoptosis, cytoskeletal
organization and cellular trafficking by binding to phos-
phorylated sites in diverse target proteins (over 300 phos-
phoproteins identified) [3-7]. In mammalian cells, seven
different isoforms have been identified (ζ,β,γ,ε,σ,η and θ)
with each isoform having distinct tissue localization and
function. 14-3-3 proteins can form homodimers or het-
erodimers that allow them to function as an adapter,
linker, scaffold or coordinator in assembling signaling
complexes [8-10]. 14-3-3 proteins associate with a
number of different signaling proteins including MEKK1,
and PI-3 kinase [11,12], apoptosis regulatory proteins
ASK-1 and tumor suppressor p53 [13-15], transcription
regulatory protein FKHRL1 and DAF-16 and histone
deacetylase [16-18]. 14-3-3 proteins promote cell survival
through their interactions with signaling proteins such as
EGFR, Raf-1, the pro-apoptotic protein BAD (Bcl-2/Bcl-XL-
antagonist causing cell death) and the cell cycle phos-
phatase cdc25 [19,20]. Furthermore, 14-3-3s may have
multiple roles in connecting signaling pathways to the
regulation of actin-based cellular changes in cytoskeleton
and cell motility [21]. Recent studies have suggested that
14-3-3 proteins are potential oncogenes [22].
Herein we hypothesized an association of 14-3-3ζ with
oral tumorigenesis. To test this hypothesis immunohisto-
chemical analysis of 14-3-3ζ protein was carried out in
paraffin embedded sections of human oral normal tis-
sues, OPLs and OSCCs and its correlation was determined
with development and progression of oral cancer. Co-
immunoprecipitation assays were carried out to deter-
mine its involvement in different signaling pathways lead-
ing to increased cell proliferation.
Methods
Patients
Institutional Human Ethics Committee approved this
study prior to its commencement. Biopsies of oral pre-
malignant lesions (leukoplakia, n = 89, including hyper-
plasias (n = 49) and dysplasias (n = 41) were collected
from patients attending Outpatient Department of
Department of Otorhinolaryngology, All India Institute of
Medical Sciences, New Delhi, India. Surgically resected
specimens of human OSCCs (n = 120) and non-malig-
nant tissues (taken from a distant site) were collected from
patients undergoing curative oral cancer surgery at
Department of Otorhinolaryngology, after obtaining
prior written consent of the patients. Normal oral tissues
with no evidence of OPLs or OSCCs, were also collected
from patients attending the Dental Outpatient Depart-
ment for tooth extraction. After excision, tissues were
immediately snap frozen in liquid N2 and stored at -80°C
till further use and one piece was collected in 10% forma-
lin and embedded in paraffin for histopathological analy-
sis. The clinical and pathological data were recorded in a
pre-designed proforma. These included clinical TNM stag-
ing (tumor, node, metastasis based on Union Interna-
tional Center le Cancer TNM classification of malignant
tumors 1998), site of the lesion, histopathological differ-
entiation, age, gender and consumption of betel quid,
areca nut and tobacco.
Cell culture and immunofluorescence
Human oral squamous carcinoma cell line, HSC2, was
used in this study. Cells were grown in monolayer cultures
in Dulbecco's modified eagle medium (DMEM-F12) sup-
plemented with 10% Fetal bovine serum (FBS) (Sigma-
Aldrich, St. Louis, MO), 100 µg/ml Streptomycin and 100
U/ml Penicillin in a humidified incubator (5% carbon-
dioxide, 95% air) at 37°C. To study the sub-cellular local-
ization of 14-3-3ζ protein, immunofluorescence (IF) was
determined in oral cancer cells. For IF, 5 × 104 cells were
plated on cover slips and grown for 48 hrs. Thereafter,
cells were washed with Phosphate buffered saline, (PBS,
0.01 M, pH = 7.2) and fixed in acetone: methanol mix-
ture(1:1) for 20 minutes. Cells were washed and perme-
ablized with 0.2% Tween in PBS followed by blocking
with 2% BSA for 1 hr. These cells were then incubated
with rabbit polyclonal anti-14-3-3ζ antibody (Santa Cruz
Biotechnology, CA) at 4°C O/N. Expression of 14-3-3ζ
protein was determined by streptavidin-conjugated-FITC
labeled secondary antibody (DAKO Cytomation, Den-
mark) as described earlier [23].
Immunohistochemical staining
Paraffin embedded sections (5 µm) of human oral normal
tissues (n = 66), OPLs (Leukoplakia, n = 89) and OSCCs
(n = 120) were collected on gelatin coated slides. For his-
topathological analysis, representative sections were
stained with hematoxylin and eosin and serial sections
were used for immunostaining as described by us previ-
ously [2]. Briefly, the sections were deparaffinized in
xylene, hydrated and pretreated in a microwave oven in
citrate buffer [0.01 M (pH 6.0)] for antigen retrieval. TheBMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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sections were incubated with hydrogen peroxide (0.3% v/
v) in methanol for 20 minutes to quench the endogenous
peroxidase activity. Non-specific binding was blocked
with 1% bovine serum albumin (BSA) in Phosphate buff-
ered saline (PBS, 0.01 M, pH = 7.2) for 1 h. Thereafter,
slides were incubated with rabbit polyclonal anti-14-3-3ζ
antibody (Santa Cruz Biotechnology Inc.) at a dilution of
1:200, for 16 hrs at 4°C and washed with PBS. The pri-
mary antibody was detected using strep-avidin-biotin
complex using DAKO LSAB plus kit (DAKO Cytomation,
Denmark) and diaminobenzidine as chromogen. All
incubations were performed at room temperature in a
moist chamber. Slides were washed with Tris-buffered
saline (TBS, 0.1 M, pH = 7.4), 3 times after every step.
Finally, the sections were counterstained with Mayer's
hematoxylin and mounted with D.P.X mountant. In neg-
ative controls, the primary antibody was replaced by non-
immune mouse IgG of the same isotype to ensure specifi-
city. OSCC tissue sections with known immunopositivity
for 14-3-3ζ protein as reported earlier [2], were used as
positive control in each batch of sections analyzed.
Evaluation of immunohistochemical staining
14-3-3ζ immunoreactivity was evaluated in five areas of
the tissue sections as described by us previously [2] and
specific staining in epithelial cells was defined as positive
staining. Tissue sections were graded as 14-3-3ζ immuno-
positive if >10% of epithelial cells showed moderate/
intense staining in cytoplasm and/or plasma membrane
and/or nucleus by two of us independently who were
blinded to clinical outcome i.e. the slides were coded and
pathologist did not have prior knowledge of the local
tumor burden, lymphonodular spread and grading of the
tissue samples while scoring the immunoreactivity.
Statistical analysis
The immunohistochemical data was subjected to statisti-
cal analysis using SPSS 10.0 software. The relationship
between 14-3-3ζ protein expression and clinicopatholog-
ical parameters was tested by Chi-Square and Fischer's
exact test. Two sided p values were calculated and p ≤ 0.05
was considered to be significant.
Immunoblot analysis of 14-3-3ζ in oral normal tissues, 
OPLs and OSCCs
Whole cell lysates were prepared from 5 normal oral tis-
sues with no evidence of malignancy, 5 OPLs (3 hyperpla-
sias and 2 dysplasias) and 8 OSCCs. Frozen tissue samples
were homogenized and lysed in IP lysis buffer containing
50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 10 mM MgCl2, 1
mM ethylene diamine-tetracetate (pH 8.0), 1% Nonidet
P-40, 100 mM sodium fluoride, 1 mM phenylmethylene-
sulphonylfluoride and 2 µl/ml protease inhibitor cocktail
(Sigma). Protein concentration was determined using
Bradford reagent (Sigma) and equal amount of protein
(80 µg/lane) from normal oral tissues, OPLs and OSCCs
was resolved on 12% sodium dodecyl sulphate(SDS)-
polyacrylamide gel. The proteins were then electro-trans-
ferred onto Polyvinylidenedifluoride (PVDF) membrane.
After blocking with 5% non-fat powdered milk in Tris-
buffered saline (TBS, 0.1 M, pH = 7.4), blots were incu-
bated with anti-14-3-3ζ antibody (1:500 dilution) at 4°C
overnight. Protein abundance of α-tubulin served as a
control for protein loading, and was determined with
mouse monoclonal anti-α-tubulin antibody (Santa Cruz
Biotechnology). Membranes were incubated with second-
ary antibody, HRP-conjugated rabbit/mouse anti-IgG
(DAKO Cytomation, Denmark), diluted at an appropriate
dilution in 1% BSA, for 2 hrs at room temperature. After
each step blots were washed thrice with Tween (0.2%)-
Tris-buffer saline (TTBS). Protein bands were detected by
Enhanced chemiluminescence method (ECL, Santa Cruz
Biotechnology, CA) on XO-MAT film.
Co-immunoprecipitation
Oral cancer cells, HSC2 were rinsed in ice-cold PBS and
lysed in IP lysis buffer. Lysates were incubated on ice for
30 minutes and cell debris was removed by centrifuga-
tion. Thereafter, lysates were pre-cleared by adding 20 µl
of protein A-Sepharose(GE Healthcare Biosciences, Swe-
den) followed by incubation with polyclonal 14-3-3ζ and
NFκB antibodies or monoclonal β-catenin and Bcl-2 anti-
bodies (at a dilution of 1:100, Santa Cruz Biotechnology)
over-night on a rocker at 4°C. Immune complexes were
pulled down by incubating with Protein A-Sepharose for
4 hrs at 4°C followed by washing with ice-cold lysis buffer
4-5 times, to eliminate non-specific interactions. Protein
A-Sepharose bound immune-complexes were then resus-
pended in Laemelli sample buffer, pH = 7.4 (10 mMTris,
10% v/v glycerol, 2% w/v SDS, 5 mM EDTA, 0.02%
bromophenol blue and 6% β-mercaptoethanol), boiled
for 5 minutes and analyzed by western blotting using spe-
cific antibodies as described above. In negative control,
primary antibody was not added to the cell lysate.
Motif search
To check the presence of 14-3-3 binding motif, peptide
sequences of 14-3-3ζ, NFκB,  β-catenin and Bcl-2 were
screened using ScanSite software available online.
Results
Immunohistochemical analysis of 14-3-3ζ in oral normal 
tissues, OPLs and OSCCs
Significant increase in 14-3-3ζ expression was observed in
different stages of oral tumorigenesis [viz. normal to
hyperplasia, dysplasia and cancer (ptrend  < 0.001)] as
revealed by Chi-Square trend analysis shown in Table 1.
The results of immunohistochemical analysis of 14-3-3ζ
protein in normal oral tissues, OPLs and OSCCs are sum-
marized in Tables 2 and 3 respectively. No detectable orBMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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faint immunostaining of 14-3-3ζ was observed in epithe-
lial cells in histologically normal oral tissues (Figure 1a),
whereas 38% of the oral normal tissues that had inflam-
mation showed cytoplasmic staining only (Figure 1b).
Increased expression (cytoplasmic/membranous/nuclear)
of 14-3-3ζ protein was observed in 33 of 48 (69%) hyper-
plasias [p = 0.009, OR = 2.8], 52% of these lesions showed
cytoplasmic expression only (Figure 1c). In addition, rap-
idly proliferating epithelial cells in the basal and paraba-
sal layers of hyperplastic lesions, showed distinct nuclear
immunopositivity (Figure 1d). Of the 41 dysplasias ana-
lyzed in this study, 67% showed immunopositivity for 14-
3-3ζ protein as shown in Figure 1e. Among the dysplasias
analyzed, an increase in overall 14-3-3ζ positivity was
observed from mild to moderate dysplasia that was sus-
tained in severe dysplasia. Furthermore, there was a differ-
ence in the sub-cellular localization of 14-3-3ζ in
dysplasias in comparison with the normal oral tissues. In
the normal oral tissues, the protein was localized in the
cytoplasm, whereas in the mild dysplasia membrane
immunopositivity was also observed, that increased in
moderate dysplasia. In addition, nuclear localization was
also observed in moderate dysplasia, which increased in
severe dysplasia. However, the number of cases showing
membrane or nuclear positivity in each sub-category was
small for statistical analysis. Nevertheless, these observa-
tions may be important in view of the role of 14-3-3ζ as
an adapter molecule in various cellular processes. The bio-
logical impact of differences in the sub-cellular localiza-
tion of 14-3-3ζ in normal, OPLs and OSCCs on the
development and progression of oral cancer remains to be
determined in a larger study.
Among OSCCs, overall immunopositivity of 14-3-3ζ pro-
tein (cytoplasmic and/or membrane/nuclear) was
observed in 95 of 120 (79%) cases analyzed as shown in
Figure 1f. Nuclear staining of 14-3-3ζ protein was
observed in 10 of 120 OSCCs (Figure 1g), whereas 6% of
OSCCs showed membranous expression in addition to
cytoplasmic staining (Figure 1h). No immunostaining
was observed in tissue sections used as negative controls
where primary antibody was replaced by isotype specific
IgG (Figure 1i), while positive control showed cytoplas-
mic expression of 14-3-3ζ protein (Figure 1j). Over-
expression of 14-3-3ζ protein in OPLs/OSCCs did not
show any correlation with age, gender, betel quid and
tobacco consumption habits, differentiation, tumor stage
or nodal status of OSCC patients (Table 2).
Sub-cellular localization of 14-3-3ζ by 
immunofluorescence in oral cancer cells
Immunofluorescence analysis was carried to validate the
sub-cellular localization of 14-3-3ζ protein in oral cancer
cells. Immunofluorescence analysis showed intense cyto-
plasmic and moderate nuclear expression of 14-3-3ζ in
oral cancer cells, HSC2, as shown in Figure 2.





14-3-3 zeta overall 
Positivity








N n (%) n (%) n (%) n (%)
Normal 66 25 (38) 25 (38) 0 0
OPLs 89 61 (69) 46 (52) 8 (9) 7 (8)
Differentiation
Hyperplasiaa 48 33 (68) 25 (52) 4 (8) 4 (8)
Dysplasia 41 28 (67) 21 (51) 4 (10) 3 (7)
Mild Dysplasiab 19 10 (53) 9 (47) 1 (5) 0
Moderate Dysplasia 14 11 (78) 8 (57) 2 (14) 1 (7)
Severe Dysplasia 8 7 (87) 4 (50) 1 (12) 2 (25)
Habits
Non consumer 12 7 (58) 5 (42) 1 (8) 1 (8)
Tobacco 
consumer
77 54 (70) 41 (53) 7 (9) 6 (8)
# OPLs: Age range:18–74 yrs, Median age, 44 yrs ; No. of Males :79 ; Females:10; Non consumers :12; Tobacco consumers (including betel quid 
usage): 77 (p > 0.05);
aNormal/Hyperplasia, p = 0.009;
bMild/Moderate/Severe Dysplasia, p = 0.123







p-value OR (95% CI)
(N) N (%)
NORMAL 66 25 (38)
OPLs 89 61 (69) <0.001*a 3.5(1.8–6.7)
OSCCs 120 95 (79) < 0.001*b 6.2(3.2–12.1)
*a Normal vs. OPLs; *b Normal vs. OSCCs.
# Normal/Hyperplasia/Dysplasia/SCC Chi Square trend Analysis, p < 0.001.BMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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Immunoblotting and co-immunoprecipitation
Further, to validate the over-expression of 14-3-3ζ protein
in oral lesions, immunoblotting was carried out in the
same tissue samples as used for immunohistochemical
analysis. Increased expression of 14-3-3ζ was observed in
OPLs and OSCCs as compared to normal oral tissues (Fig-
ure 3a). These findings are in concordance with the
immunohistochemical data. α-tubulin served as an inter-
nal control for equal loading of protein in each well of
SDS-PAGE (Figure 3b).
As a first step in determining the functional significance of
14-3-3ζ in oral carcinogenesis, we identified its binding
partners in oral cancer cells, HSC2, using co-immunopre-
cipitation (IP). Immunoprecipitation of 14-3-3ζ protein
revealed its binding to p65 subunit of NFκB, β-catenin
and Bcl-2 proteins (Figure 4a) suggestive of its involve-
ment in inflammation, survival and proliferation of can-
cer cells. Reverse immunoprecipitation assays using
specific antibodies for NFκB, β-catenin and Bcl-2 proteins
confirmed their binding to 14-3-3ζ (Figure 4b). However,
no band was observed in immunoblot analysis in nega-
tive controls. Motif search using Scansite software
revealed the presence 14-3-3 binding motif, Mode 1 in
NFκB, β-catenin and Bcl-2 proteins (Figure 5).
Discussion
Herein, we demonstrate for the first time that over-expres-
sion of 14-3-3ζ occurs in pre-malignant stages of oral can-
cer, as early as in hyperplasia and elevated expression is
sustained down the tumorigenic pathway. In hyperplastic
and dysplastic tissues, epithelial cells in the rapidly prolif-
erating basal layer showed nuclear staining in addition to
cytoplasmic localization of 14-3-3ζ protein, suggesting
that it may be involved in nuclear cytoplasmic shuttling of
proteins in rapidly proliferating cells. Our immunofluo-
rescence results also showed cytoplasmic and nuclear
localization of 14-3-3ζ in oral cancer cells, HSC2, con-
firming the immunohistochemistry data. These findings
are also supported by other studies which demonstrate
abundant cytoplasmic and nuclear localization of several
14-3-3 isoforms, including 14-3-3ζ [24-26]. Hemert et al.
[27] proposed that the nucleo-cytoplasmic shuttling of
14-3-3ζ in mammalian cells (Hela and HaCat cells) may
have a role in regulation of cellular processes. Interest-
ingly, the nuclear/cytoplasmic expression of 14-3-3ζ pro-
tein has also been proposed to be involved in cell cycle
regulation and DNA replication during embryonic devel-
opment in Drosophila melanogaster, C. elegans and Xenopus
laevis [28-30]. Currently studies are underway to deter-
mine the functional significance of 14-3-3ζ localization in
different sub-cellular compartments in oral cancer cells.
Major thrust in understanding the biology of oral cancer
has been laid on unraveling the proteins involved in
malignant transformation, while the early events involved
in genesis of pre-neoplastic lesions remain largely
obscure. However, in recent years there has been a para-





14-3-3 zeta overall 
Positivity








N n (%) n (%) n (%) n (%)
OSCC 120 95 (79) 77 (65) 8 (6) 10 (8)
Differentiation
WDSCC 67 51 (76) 43 (64) 4 (6) 4 (6)
MDSCC 47 39 (83) 29 (61) 4 (8) 6 (12)
PDSCC 6 5 (83) 5 (83) 0 0
Tumor Stage
T1 20 17 (85) 15 (75) 1 (5) 1 (5)
T2 36 24 (66) 18 (50) 2 (5) 4 (11)
T3 32 27 (84) 19 (60) 5 (15) 3 (9)
T4 32 27 (84) 25 (78) 0 2 (6)
Nodal Status
N- 66 51 (77) 43 (65) 4 (6) 4 (6)
N+ 54 44 (81) 34 (63) 4 (7) 6 (11)
Habits
Non consumer 16 12 (75) 10 (62) 1 (6) 1 (6)
Tobacco 
consumer
104 83 (80) 67 (64) 7 (7) 9 (9)
# OSCCs: Age Range: 29–75 yrs, Median age, 53 yrs; No. of Males: 95; Females:25 ; Non consumers :16; Tobacco consumers (including betel quid 
usage):104 (p > 0.05) No correlation was observed between 14-3-3ζ protein expression and histopathological grading, tumor stage and nodal status 
of OSCCs.BMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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Immunohistochemical analysis of 14-3-3ζ in oral tissues Figure 1
Immunohistochemical analysis of 14-3-3ζ in oral tissues. Paraffin embedded oral tissue sections were stained using anti-14-3-3ζ 
antibody as described in Materials and Method section. (a) Normal oral mucosa showing no detectable immunostaining of 14-
3-3ζ protein (original magnification ×100). (b) Inflamed normal oral mucosa showing cytoplasmic immunostaining of 14-3-3ζ 
protein (original magnification × 100). (c) Oral hyperplasia showing cytoplasmic and nuclear immunostaining of 14-3-3ζ(original 
magnification × 100). (d) Oral hyperplasia showing nuclear and cytoplasmic immunostaining at higher magnification (original 
magnification × 400). (e) Dysplastic lesion showing cytoplasmic immunostaining in epithelial cells (original magnification × 200). 
(f) OSCC showing cytoplasmic and nuclear staining in tumor cells (original magnification × 100). (g) OSCC showing cytoplas-
mic and nuclear staining in tumor cells (original magnification × 400). (h) OSCC showing cytoplasmic and membranous staining 
in tumor cells (original magnification × 400). (i) Negative control showing no immunostaining of 14-3-3ζ protein in epithelial 
cells (original magnification × 100). (j) Positive control is a known esophageal squamous cell carcinoma showing cytoplasmic 
immunostaining of 14-3-3ζ in epithelial cells (original magnification × 100). Arrow shows nuclear staining in Panels 1d, 1e and 1 
h and membranous staining in Panel 1 g respectively.BMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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Immunoblot analysis of 14-3-3ζ in oral tissues Figure 3
Immunoblot analysis of 14-3-3ζ in oral tissues. Equal amounts of whole cell lysates of normal oral tissues (N), OPLs (P) and 
OSCCs (C) from the same patients as used for IHC were resolved on 12% SDS-PAGE. Proteins were then electro-transferred 
on PVDF membrane followed by blocking with 5% non-fat milk O/N. Blots were incubated with anti-14-3-3ζ polyclonal anti-
body and protein expression was determined using Enhanced chemiluminescence method. Immunoblots of: (a) 14-3-3ζ protein 
and (b) α-tubulin, in normal oral tissue (N), oral pre-malignant lesion (P) and OSCC (C).
N              N              P           P          C         C






Immunofluorescence of 14-3-3ζ protein in oral cancer cells, HSC2 Figure 2
Immunofluorescence of 14-3-3ζ protein in oral cancer cells, HSC2. Cells were fixed and immunolabeled with anti-14-3-3ζ anti-
body followed by streptavidin-conjugated-FITC labeled secondary antibody (Green fluorescence) and nuclei were counter-
stained with propidium iodide (red fluorescence). (a) Nuclei showing red fluorescence of Propidium Iodide. (b) Green 
fluorescence in cytoplasm and nucleus of HSC2 cells. (c) Merged figure showing localization of 14-3-3ζ protein in oral cancer 
cells (a-c, original magnification × 200).BMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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digm shift in discovery of new drugs for cancer manage-
ment. The focus has shifted from cancer treatment to
prevention. It is becoming increasingly clear that atten-
tion needs to be focused on rational designing of chemo-
preventive agents directed towards specific molecular
targets that are altered in early stages, prior to malignant
transformation for effective intervention in the carcino-
genic process. The upregulation of 14-3-3ζ at transcrip-
tional and translational levels in early stages of oral
tumorigenesis prompted us to hypothesize that 14-3-3ζ
may be a link between chronic inflammation and cancer.
To test this hypothesis, we carried out Co-immunoprecip-
itation assays to identify its binding partners in oral cancer
cells. Our results demonstrated binding of 14-3-3ζ to
NFκB, β-catenin and Bcl-2 in these cells. In this context,
the interaction of 14-3-3ζ with NFκB is of major impor-
tance and suggestive of its probable role in linking inflam-
mation and proliferation of oral epithelial cells. It is
noteworthy that in our earlier study, we showed transcrip-
tional upregulation and increased expression of NFκB and
14-3-3ζ in oral premalignant lesions (hyperplasia and
dysplasia) and oral cancer [31]. Our present findings are
also supported by the recent study of Aguilera et al. [32]
which showed that 14-3-3 proteins facilitate the nuclear
export of IκBα-p65 complex and are required for the
appropriate regulation of NFκB signaling after treatment
with tumor necrosis factor alpha (TNFα). Thus, nucleo-
cytoplasmic shuttling of 14-3-3s may have a role to play
in translocation of NFκB from cytoplasm to nucleus in
presence of specific stimulus.
Immunoblot analysis after Co-immunoprecipitation assay Figure 4
Immunoblot analysis after Co-immunoprecipitation assay. Immunoprecipitation assays of 14-3-3ζ, NFκB, β-catenin and Bcl-2 
proteins were carried out in oral cancer cells, HSC2, as described in Materials and Method section. The immunoprecipitates 
were resolved on 12% SDS-PAGE and electro-transferred on PVDF membrane followed by blocking with 5% non-fat milk O/N. 
Blot was incubated with 14-3-3ζ antibody and protein expression was determined using Enhanced Chemiluminescence 
method. Figure 4a shows immunoblot analysis 14-3-3ζ, demonstrating the binding of 14-3-3ζ protein with NFκB, β-catenin and 
Bcl-2 proteins. However, no band of 14-3-3ζ was observed in the negative control. Similarly, reverse immunoprecipitation 
assays were carried out using specific antibodies for NFκB, β-catenin and Bcl-2 proteins. Figure 4b shows immunoblot analysis 
















IP E-cateninBMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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Motifscan of 14-3-3 binding motif Mode1 Figure 5
Motifscan of 14-3-3 binding motif Mode1. Using Scansite software http://www.motifscan.mit.edu, motif search showed pres-




(a) NFkBBMC Cancer 2007, 7:169 http://www.biomedcentral.com/1471-2407/7/169
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In an attempt to understand the functional significance of
increased expression of 14-3-3ζ in oral carcinogenesis, we
carried out co-immunoprecipitation assays to identify the
binding partners of 14-3-3ζ and showed its binding to β-
catenin. It is noteworthy that β-catenin, functioning as a
major component of both Wnt signaling and cell-cell
adhesion, plays a central role in cell proliferation, differ-
entiation, polarity, morphogenesis, and development
[33-35]. Interestingly, 14-3-3ζ, in association with β-cat-
enin, has been shown to facilitate transactivation of β-cat-
enin by AKT [36]. In turn, the transactivation of β-catenin
increases the transcription of genes that promote tumor
cell growth, such as MYC [37], CCND1 (which encodes
cyclin D) [38,39] and JUN [40]. Using immunoprecipita-
tion Fang et al. [41], demonstrated that phosphorylation
of β-catenin at serine 552 leads to its dissociation from
cell-cell contacts, increases its binding to 14-3-3ζ and its
transcriptional activity. It is noteworthy that in a parallel
study in our laboratory, we showed loss of membranous
β-catenin and its nuclear accumulation to be adverse
prognosticators in OSCC patients (Sawhney et al., per-
sonal communications). We have previously reported
increased cyclin D1 protein expression in OPLs and
OSCCs and proposed that deregulation of the p16/pRb/
cyclin D1 pathway is an early event in the acquisition of
dysplasia, but deregulation of both pRb and p53 path-
ways is associated with malignant transformation and
adverse prognosis in oral tumorigenesis [42]. Taken
together, the present study suggests that β-catenin is one
of the targets of 14-3-3ζ that may be implicated in cellular
pathways involved in increased cell proliferation.
Hyperproliferation of cancer cells is not only attributed to
increase cell division but also to deregulation of apopto-
sis. In this context, we demonstrated the binding of 14-3-
3ζ with Bcl-2 in oral cancer cells and propose that the
interaction of 14-3-3ζ with Bcl-2 may result in its seques-
tration and consequent abrogation of apoptosis. Our
findings are in accord with the well established role of 14-
3-3 proteins in abrogation of apoptosis by sequestering
Bcl-2 or its family members (Bad, Bax) [43-45]. In-depth
analysis of these interactions is currently underway to elu-
cidate their functional significance in oral carcinogenesis.
Interestingly, over-expression of 14-3-3ζ has also been
reported in esophageal squamous cell carcinomas [46],
lung [47] and stomach cancer [48], supporting our find-
ings in OSCCs and underscoring the importance of this
protein in human cancers. In view of the above in depth
analysis of the functional significance of 14-3-3ζ in oral
carcinogenesis is warranted.
Conclusion
This study demonstrates increased expression of 14-3-3ζ
as early as in oral hyperplasia and its sustained expression
down the carcinogenic pathway. Our results suggest
involvement of 14-3-3ζ in cell signaling pathways
involved in inflammation, cell proliferation and abroga-
tion of apoptosis during oral carcinogenesis. Hence, the
upregulation of 14-3-3ζ expression in early pre-neoplastic
stages of oral tumorigenesis, both at transcriptional and
translational levels, underscores the need for an in-depth
analysis of it being one of the putative links between
chronic inflammation and cancer.
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